143 results about "Drosophila ornatifrons" patented technology

The present invention relates to Drosophila models of the neurodegenerative disorder spinocerebellar ataxia 1 (SCA-1). In particular, the invention relates to transgenic Drosophila which express normal human ataxin-1 or mutant human ataxin-1 with expanded polyglutamine repeats for SCA-1 therapeutics. The invention further relates to the diagnosis of predispositions to developing SCA-1. The invention further relates to methods of using the transgenic Drosophila to screen for therapeutics of SCA-1 and other neurodegenerative disorders. The invention further relates to the identification of modifier genes of the SCA-1 phenotypes produced by overexpression of ataxin-1, for therapeutic and diagnostic uses and for screening for therapeutics of SCA-1 and other neurodegenerative disorders. The invention further relates to the diagnosis of a predisposition to SCA-1 comprising detecting the overexpression of normal ataxin-1.

Provided is a special Drosophila strain having a Bradeion gene artificially incorporated therein to exclusively express the gene in the compound eyes and thus to exhibit rough eye. The Drosophila strain has the following properties:

• (a) a human-derived Bradeion gene has been transferred in the strain to express the human-derived protein Bradeion in the compound eyes from the developmental period;
• (b) the compound eyes show morphological abnormality due to the expression of Bradeion; and
• (c) the morphological abnormality occurring in the compound eyes is multiplied according to the number of transferred Bradeion genes.

The invention discloses a method for extracting coreopsis tinctoria procyanidins and an application of the coreopsis tinctoria procyanidins in delaying senescence. The method comprises the following steps: extracting coreopsis tinctoria procyanidins from the raw material coreopsis tinctoria which grows 2600m over the sea level by adopting a dynamic high-pressure microfluidization assisted extraction technology for 30 minutes with 70% ethanol at the extracting pressure of 120MPa and the extracting temperature of 50 DEG C, and treating the coreopsis tinctoria twice by means of microjet pressure. The total antioxidation activity of the prepared procyanidins is higher than that of ascorbic acid, and has an effect of delaying senescence of drosophila melanogaster by combining results of drosophila melanogaster surviving experiments and in-vivo biochemical index detection; liver injury experiments in mice indicate that the procyanidins extracted from coreopsis tinctoria is capable of reducing the activities of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) in serum and playing a certain role in protecting CC14 caused liver injury in mice. According to the application, the procyanidins extracted from coreopsis tinctoria have an excellent effect of delaying senescence, and has a wide practical value.

The present invention discloses a preparation method and an application of a mussel oligopeptide, and belongs to the field of marine biotechnology application. The preparation method comprises: adopting mytilus edulis as a raw material, and adopting an alkaline cold extraction method to obtain mussel protein from mussel freeze-drying powder; and carrying out composite enzymolysis of protein to obtain mixed polypeptides, carrying out ultra-filtration to obtain the oligopeptide, adopting aging mouse models to carry out a series of anti-aging animal experiments and behavioral experiments, and carrying out a drosophila survive experiment to prove aging delay activity of the mussel oligopeptide so as to create a new approach for achievement of scientific and high-value mussel utilization. Compared with the method in the prior art, the method of the present invention has the following advantages that: the mussel protein is extracted and prepared, the optimal protease and the preferred process are adopted to carry out enzymolysis purification on the mussel protein, decomposition on the mussel protein molecule structure due to the high temperature is avoided, the grading of the mussel polypeptide at the molecular weight level is achieved, and the obtained mussel oligopeptide has the pure and good aging delay effect.

The present invention relates to a construction method of a human dcf1 gene transgenic drosophila melanogaster model. According to the invention, a drosophila melanogaster transgenic vector pUAST-dcf1 is constructed; a human dcf1 transgenic UAS drosophila melanogaster strain is obtained through microinjection; and human dcf1 transgenic drosophila melanogaster strains, with balance gene and genetic stability, of w, UAS-dcf1/Cyo and Tm6B/Tm2 are obtained through hybrid and backcross of the human dcf1 transgenic UAS drosophila melanogaster strain with Double Balance drosophila melanogasters of w, B1/Cyo and Tm6B/Tm2. The present invention utilizes microinjection gene engineering technology and drosophila melanogaster hybridization technology to construct the human dcf1 gene transgenic drosophila melanogaster model, and provides materials and new ideas for research on relative neurodegenerative diseases.

The invention belongs to the technical field of gene engineering, and in particular relates to a formica sinensis acetylcholin esterase (AChE) gene, encoded formica sinensis acetylcholin esterase (AChE) and a method for preparing the enzyme. The base sequence and the amino acid sequence of the formica sinensis AChE gene and the encoded formica sinensis AChE are as shown in a sequence list. The preparation method of the enzyme comprises the following steps: (1) constructing a formica sinensis AChE gene complete sequence and carrying out polymerase chain reaction (PCR) amplification; (2) constructing an eukaryotic expression recombinant vector of the formica sinensis AChE gene complete sequence; (3) converting a pichia pastoris host cell, cultivating and inducing expression; and (4) purifying. Experiments prove that the prepared formica sinensis AChE, compared with the existing drosophila melanogaster AChE, is higher in activity and sensitivity; therefore, the formica sinensis AChE has a relatively good application prospect in the technical field of future pesticide detection reagent preparation.

Transgenic flies displaying altered phenotypes due to expression of the Abeta and C99 portions of the human APP gene are disclosed. Use of these flies in a method to identify Drosophila genes and the human homologs of these Drosophila genes, that are potentially involved in Alzheimer's Disease, is also disclosed. The use of said human homologs as drug targets for the development of therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway, as well as pharmaceutical compositions comprising substances directed to these genes, are also disclosed.

The invention relates to an efficient heterogeneous expression production process of drosophila antitumor activity protein rd-1, comprising the following steps of designing and synthesizing corresponding probes, selecting gene for encoding the protein from a cDNA library constructed by adopting SMART technology according to the sequencing result of an N end and a C end of the protein, by carrying out modification of condon preference and ribosome bind site on the protein, connecting the tb1 gene and pPIC9 carrier to construct pPIC9-tbi expression carrier, switching the expression carrier into GS115 Pichia pastoris expression host strain by electroporation, constructing recombinant Pichia pastoris engineering bacteria and expressing in Pichia pastoris, determining the additive amounts by optimizing fermentation condition as follows: 4% of glycerol, 1.25% of YNB, pH 6.0 of culture medium and 1% of methanol induced concentration and obtaining the optimized fermentation time of 84h. The rd-1 protein prepared by the invention has higher antitumor bioactivity and smaller toxic and adverse effect, and can be served as main ingredients of health care products.

The invention provides a method for detecting spotted wing drosophila, belongs to the technical field of insect quarantine, and particularly relates to a method for detecting spotted wing drosophila. The method comprises the following steps of: extracting a sample genome DNA; amplifying a mitochondrial COI gene sequence and recovering amplification fragments: based on the genomic DNA sample as a template, amplifying the mitochondrial COI gene sequence by adopting COI-F and COI-R, and recovering amplification products; and respectively digesting the amplification fragments by adopting restriction enzyme Apa I and Hinf I, and carrying out agarose gel electrophoresis on digestion products, wherein, two digestion fragments with the lengths of 150-200 and 330-370 are respectively obtained when adopting the restriction enzyme Apa I for digesting the amplification fragments, and the amplification fragments are not cut when adopting the restriction enzyme Hinf I for digesting the amplification products, and at the time, the sample is the spotted wing drosophila. The method is simple, convenient, accurate and sensitive to operate.

The invention belongs to the technical field of biomedicine, and in particular relates to a preparation method and application of a recombinant EBV gHgL immunogen. The polymerase chain reaction PCR technology is used to obtain gene fragments of gH and gL, the two target fragments are separately cloned into an insect expression vector pMT, endotoxin is removed through plasmid large-scale extraction, then the two target fragments and a resistance screening plasmid pCoBlast are co-transfected into Drosophila melanogaster Schneider2 cells, blasticidin is used for positive clone screening, and stable S2 cell lines for efficiently secreting and expressing gHgL are screened out. After expanded culture, the gHgL with high uniformity, high yield and high natural fidelity is obtained through two steps of purification of nickel column affinity chromatography and gel filtration chromatography. The interaction between the gHgL and a receptor EphA2 is verified by the micro-scale thermophoresis technology, and thereby the gHgL is suitable as an immunogen for the research and development of EBV subunit vaccines, and combined vaccines with gB and gp350.

The invention discloses an attractant for Drosodhila suzukii Matsumura and an application method thereof. The attractant is prepared by mixing glutamic acid, cane sugar, table salt, an odor attractantand a color attractant according to a weight ratio of (80-100): 20: (20-25): (20-25): (5-6). The attractant starts to exert an attracting effect when the concentration of an attractant aqueous solution is 3 g/L or above, has stronger attractive force with higher concentration, and achieves an effective distance of 5 to 30 meters. According to the invention, the Drosodhila suzukii Matsumura has acharacteristic of needing to supplement a great amount of nutrients in a period of time during the process of development; the tendency of the Drosodhila suzukii Matsumura to some colors and smells iscomprehensively utilized; the attractant is used by cooperating with pesticides like avermectin, spinosad and highly-efficient cypermethrin; thus, trap-killing and toxic-killing effects are greatly improved, and the number of a Drosodhila suzukii Matsumura population can be greatly reduced.

The invention relates to a construction method and application of a drosophila model for simulating human diseases, in particular to a construction method and application of a drosophila model for axonal Charcot-Marie-Tooth (CMT2). The model constructs the amino acid mutation of the endogenous corresponding human ATP1A1 gene of the Drosophila by a genome editing method, and evaluates the pathological phenotype by utilizing the changes of brain nervous system loop, biological clock related behavior, life span and exercise ability. The model and the pathological evaluation means established by the invention have the advantages of simple operation and strong repeatability, and the obtained CMT2 drosophila model can be used for researching the pathological process and mechanism of the disease,can also be used for screening and verifying medicines for delaying or treating the CMT2 disease on a large scale, and has a good application prospect.

The invention discloses MRRP protein, a gene, a carrier, engineering bacteria and application of the MRRP protein, the gene, the carrier and the engineering bacteria to preparation of wound healing medicine. The MRRP protein is formed by sequentially connecting mussel attachment protein Ma1, elastic drosophila melanogaster protein Res1, a spider silk protein nitrogen end sequence Nt1, a spider silk protein middle-piece repetitive sequence SSR, a spider silk protein carbon end sequence Ct1, elastic drosophila melanogaster protein Res2 and mussel attachment protein Ma2. The MRRP protein integrates self-assembling performance of spider silk protein, high elasticity of the elastic drosophila melanogaster protein and high viscosity of the mussel attachment protein, comprehensive performance is excellent, lengths are uniform, the MRRP protein can be biodegraded completely, the yield is high by adopting a microorganism method for preparing, and chemical pollution is avoided; the MRRP protein has high elasticity, and can bond wounds, so that the wounds are bonded without using lines.

The invention belongs to the field of medicines, and particularly relates to an application of drosophila melanogaster Hsp22 protein in preparation of anti-tumor drug. The pharmacological activity experiment part evaluates the treatment effect of the drosophila melanogaster Hsp22 protein on a Ras tumor drosophila melanogaster model and the treatment effect on a mouse tumor model, and finds that the drosophila melanogaster Hsp22 protein has good antitumor activity. The drosophila melanogaster Hsp22 protein can be used for developing novel anti-tumor drugs and has important medical prospects andeconomic value.

The present application provides a vector for trapping an unknown gene of Drosophila melanogaster, which is a recombinant plasmid comprising the following nucleotide sequences in this order: an artificial consensus splicing acceptor site; a synthetic “stop/start” sequence; a reporter gene; a drug resistance gene; a gene responsible for a detectable phenotype of the Drosophila melanogaster; and a synthetic splicing donor site. The present application also provide a method for trapping an unknown gene of Drosophila melanogaster by using the vector.

Plynucleotides encoding a novel Drosophila gene product designated mus101 and homologues thereof as well as mus101 polypeptides are provided. Polynucleotide probes derived from the nucleotide sequence of mus101 and antibodies that bind to mus101 protein are also provided as well as assays for identifying substances that regulate mus101 function.

The invention discloses a drosophila trapping and killing device with a drosophila capturing attractant and relates to the field of pest control. The device comprises a bottle body as well as a bottle opening and a bottle cover arranged on the bottle body, wherein a connecting structure for connecting an object is arranged above the bottle cover; the bottle body comprises channels which are arranged on the bottle body for drosophila to enter into the bottle body, a rainproof cover which is arranged above the channels and around the bottle body and a base plate which is arranged in the bottom of the bottle body for holding the drosophila capturing attractant; the channel contracts from outside to inside to form a channel inlet on the side wall of the bottle body, a channel outlet in the inner cavity of the bottle body and a contraction piece between the channel inlet and the channel outlet; the drosophila capturing attractant comprises: (1) fruit and vegetable foods, a beverage, yeast, table vinegar, a sweetening agent, an insecticide and water; or (2) a beverage, table vinegar, a sweetening agent and an insecticide. The device disclosed by the invention is simple in structure, low in manufacturing cost and good in drosophila trapping and killing effect.